Phoenix Molecular Designs

Focus: Phoenix Molecular Designs is a Vancouver-based public biotech company focused on kinase inhibition for oncology and hematology indications. The company operates at an early stage with a focused pipeline in cancer therapeutics.

Oncology Hematology

Profile data last refreshed 20h ago · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Open Jobs

About Phoenix Molecular Designs

AI assessmentNot Hiring

No open roles listed right now. Follow Phoenix Molecular Designs to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

PMD-026

Myelofibrosis

Phase 1

Clinical Trials (1)

NCT07379125Therapeutic RSK1 Targeting in Myelofibrosis

Phase 1

Help build intelligence for Phoenix Molecular Designs

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Exposure to kinase inhibition—a mature, well-validated modality with clear IP and commercial benchmarks in oncology
Public company status provides liquidity and institutional stability rare for early-stage biotech
Opportunity to shape foundational science and clinical strategy at a company with only 2 active trials

Watch Out For

Zero active job openings and no hiring data suggest the company may be in a hold or contraction phase
No revenue, no published data (0 publications), and minimal pipeline depth (only 1 Phase 1/2 program) indicate pre-clinical or very early clinical stage with significant de-risking ahead

Generated by Claude from Phoenix Molecular Designs's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

PMD-026

Metastatic Breast Cancer

Phase 1/2

Clinical Trials (1)

NCT04115306Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

Phase 1/2